Article Text

PDF
AB0993 Elderly - onset sarcoidosis: a single center comparative study
  1. S Kobak1,
  2. F Sever2,
  3. H Semiz3,
  4. M Orman4
  1. 1Rheumatology, Istinye University Faculty of Medicine, LIV Hospital, Istanbul
  2. 2Chest Diseases, Medicalpark Hospital
  3. 3Internal Medicine
  4. 4Statistics, Ege University Faculty of Medicine, Izmir, Turkey

Abstract

Background Sarcoidosis is a chronic granulomatous inflamatory disease characterized with non-caseified granuloma formation. It is rarely affects patients older than 65 years old.

Objectives The purpose of this study is to compare and evaluate the demografic, clinical and laboratory features of elderly-onset (EOS) and young-onset sarcoidosis (YOS) patients.

Methods One hundred and thirty one patients diagnosed with sarcoidosis according to clinical, radiologic and histopathological evaluation were included in this study.The patients with initial symptoms started after age 65 were accepted as EOS. Demografic, clinic, radiologic, and laboratory data and the medication which the patients recieved were recorded and retrospectively evaluated.

Results Twenty (15.3%)of 131 patients were diagnosed as EOS, and 111 (84.7%) patients were evaluated as YOS. Fifteen of 20 EOS patients were female and 5 of them were male. Average duration of the disease was determined as 38.4months for YOS and 22.5months for EOS (p=0.556).Delay of the diagnosis was 12months for YOS while it was 3months for EOS (p=0.001).Higher rates of fatique, comorbid diseases and more Hydroxychloroquine (HQ) use were detected in EOS patients comparing to YOS (p=0.010, p=0.003 and p=0.039 respectively).There was obviously more disease modifying anti-rheumatic drugs (DMARDs) use by YOS group but statistical difference wasn't significant. The 3-year survival rate after diagnosis of sarcoidosis was %95 in the EOS group, compared with %100 in the YOS group.

Conclusions In this study we showed that YOS and EOS patients may be presented with different clinical, and laboratory features. EOS patients are characterized with higher rates of fatique and comorbid diseases, less inflammatory sign and delayed diagnosis, and less DMARDs usage.

References

  1. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336: 1224±1234.

  2. Chen ES, Moller DR. Etiology of sarcoidosis. Clin Chest Med. 2008; 29:365–377.

  3. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65.

  4. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. J Am Med Assoc. 2011;305:391–9.

  5. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med.2001;164:1885–9.

References

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.